Metcalf, Matthew C.
Janus, Benjamin M. http://orcid.org/0000-0002-6290-8300
Yin, Rui http://orcid.org/0000-0001-5330-8306
Wang, Ruixue
Guest, Johnathan D.
Pozharski, Edwin http://orcid.org/0000-0001-7012-5376
Law, Mansun http://orcid.org/0000-0002-8934-9756
Mariuzza, Roy A. http://orcid.org/0000-0003-0748-5875
Toth, Eric A. http://orcid.org/0000-0002-0766-5131
Pierce, Brian G. http://orcid.org/0000-0003-4821-0368
Fuerst, Thomas R. http://orcid.org/0000-0002-9766-9995
Ofek, Gilad http://orcid.org/0000-0002-0677-4467
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI168048)
Article History
Received: 27 January 2023
Accepted: 22 June 2023
First Online: 5 July 2023
Competing interests
: The authors declare the following competing interests: B.G.P., T.R.F., E.A.T., and J.D.G. are co-inventors on a pending patent application (US application 18/252800) filed by the University of Maryland based on the secreted E1E2 design used in this study. T.R.F. is a co-founder and holds stock in NeuImmune, Inc., a company focused on glycoprotein-based vaccines and therapeutics. All the other authors declare no competing interests.